| MRK |
Report |
Total revenue |
IN-LINE |
pred ~$16.45B vs. cons $16.33B |
MEDIUM |
| MRK |
Report |
KEYTRUDA / KEYTRUDA QLEX sales |
IN-LINE |
pred ~$8.14B vs. cons $8.08B |
MEDIUM |
| MRK |
Report |
WINREVAIR sales |
BEAT |
pred ~$0.64B vs. cons $0.61B |
MEDIUM |
| MRK |
Guide |
FY2026 revenue guidance |
UNCHANGED |
guide ~$66.40B midpoint vs. cons $66.40B midpoint (FY2026) |
HIGH |
| MRK |
Guide |
FY2026 non-GAAP EPS guidance, including Terns effects |
LOWER |
guide ~$2.62 midpoint vs. cons $2.66 midpoint (FY2026) |
MEDIUM |
| MRK |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.2% |
— |
MEDIUM |
| MRK |
Return |
5-day cumulative residual |
+0.3% (FADE) |
A modest sales/WINREVAIR-led beat should initially outweigh the mechanically acquisition-distorted EPS print, but the FY2026 EPS midpoint of ~$2.62 versus ~$2.66 consensus embeds incremental Terns financing/development drag and leaves little room for upward out-period revisions; the initial ~+1.2% residual is therefore likely to fade toward ~+0.3% by day five. |
MEDIUM |